BRPI0817158A2 - "método de identificar um paciente com câncer renal, kit, métodos e conjunto de compostos" - Google Patents

"método de identificar um paciente com câncer renal, kit, métodos e conjunto de compostos"

Info

Publication number
BRPI0817158A2
BRPI0817158A2 BRPI0817158A BRPI0817158A2 BR PI0817158 A2 BRPI0817158 A2 BR PI0817158A2 BR PI0817158 A BRPI0817158 A BR PI0817158A BR PI0817158 A2 BRPI0817158 A2 BR PI0817158A2
Authority
BR
Brazil
Prior art keywords
kit
identify
methods
cancer patient
kidney cancer
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Inventor
Daniel S Chen
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0817158A2 publication Critical patent/BRPI0817158A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0817158 2007-11-09 2008-11-05 "método de identificar um paciente com câncer renal, kit, métodos e conjunto de compostos" BRPI0817158A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98688407P 2007-11-09 2007-11-09
PCT/US2008/082456 WO2009061800A2 (en) 2007-11-09 2008-11-05 Methods and compositions for diagnostic use in cancer patients

Publications (1)

Publication Number Publication Date
BRPI0817158A2 true BRPI0817158A2 (pt) 2015-04-14

Family

ID=40342593

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817158 BRPI0817158A2 (pt) 2007-11-09 2008-11-05 "método de identificar um paciente com câncer renal, kit, métodos e conjunto de compostos"

Country Status (13)

Country Link
US (2) US20090123930A1 (enExample)
EP (1) EP2222874A2 (enExample)
JP (1) JP2011502513A (enExample)
KR (1) KR20100095571A (enExample)
CN (1) CN101910416A (enExample)
AU (1) AU2008324782A1 (enExample)
BR (1) BRPI0817158A2 (enExample)
CA (1) CA2703258A1 (enExample)
IL (1) IL205246A0 (enExample)
MX (1) MX2010005057A (enExample)
RU (1) RU2010123381A (enExample)
WO (1) WO2009061800A2 (enExample)
ZA (1) ZA201002808B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG177640A1 (en) * 2009-07-13 2012-02-28 Genentech Inc Diagnostic methods and compositions for treatment of cancer
KR101557545B1 (ko) * 2009-09-17 2015-10-06 에프. 호프만-라 로슈 아게 암 환자에서 진단 용도를 위한 방법 및 조성물
CN104634971A (zh) * 2010-07-19 2015-05-20 霍夫曼-拉罗奇有限公司 鉴定响应抗癌疗法的可能性升高的患者的方法
WO2012010549A1 (en) * 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
US10260097B2 (en) 2011-06-02 2019-04-16 Almac Diagnostics Limited Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
CA2862835A1 (en) * 2012-01-13 2013-07-18 Genentech, Inc. Biological markers for identifying patients for treatment with vegf antagonists
WO2014001232A1 (en) * 2012-06-26 2014-01-03 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
HK1214633A1 (zh) * 2012-12-03 2016-07-29 Almac Diagnostics Limited 癌症的分子诊断测试
US11015190B2 (en) 2013-09-17 2021-05-25 Lucence Life Sciences Pte Ltd Method of treating a patient having renal cancer
GB201409479D0 (en) * 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
MX2017007535A (es) * 2014-12-09 2017-08-10 Merck Sharp & Dohme Sistema y metodos para derivar biomarcadores de firmas geneticas de la respuesta a antagonistas de muerte programada 1 (pd-1).
KR101903522B1 (ko) * 2015-11-25 2018-11-23 한국전자통신연구원 다차원 건강데이터에 대한 유사사례 검색 방법 및 그 장치
WO2025098316A1 (en) * 2023-11-09 2025-05-15 Sun Jet Biotechnology Inc. Apolipoprotein a-ii biomarkers for detecting and monitoring cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027216A1 (en) * 2001-07-02 2003-02-06 Kiernan Urban A. Analysis of proteins from biological fluids using mass spectrometric immunoassay
EP1869216B1 (en) * 2005-04-13 2012-08-15 Oncotest GmbH Gene expression profiles being predictive for the response of tumors to pharmaceutically effective compounds
WO2007123722A2 (en) * 2006-03-31 2007-11-01 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy

Also Published As

Publication number Publication date
JP2011502513A (ja) 2011-01-27
RU2010123381A (ru) 2011-12-20
IL205246A0 (en) 2010-12-30
WO2009061800A3 (en) 2009-07-16
ZA201002808B (en) 2011-07-27
US20090123930A1 (en) 2009-05-14
US20110151468A1 (en) 2011-06-23
CA2703258A1 (en) 2009-05-14
AU2008324782A1 (en) 2009-05-14
CN101910416A (zh) 2010-12-08
WO2009061800A2 (en) 2009-05-14
EP2222874A2 (en) 2010-09-01
KR20100095571A (ko) 2010-08-31
MX2010005057A (es) 2010-05-19

Similar Documents

Publication Publication Date Title
DK1997793T3 (da) Heteromolekylære metal-humussyre-komplekser (chelater)
DE602005024846D1 (de) Blutdialysator
IL197217B (en) Novel anti-cd38 antibodies for the treatment of cancer
ZA201202510B (en) Artificial kidney
IL225386A (en) Method for diagnosis of cancer by detecting an ereg protein
BRPI0719626A2 (pt) '' composto ''
EP1971389A4 (en) REMOVABLE BLOOD LINE FILTER
ATE499453T1 (de) Zugerichtetes leder
EP1855738A4 (en) CATHETER CONNECTOR
EP2171592A4 (en) PARALLELIZATION OF SEQUENCIAL FRAMEWORK CONDITIONS USING TRANSACTIONS
PT2170956E (pt) Tratamento de tumores utilizando um anticorpo anti-l1 específico
DE602005022650D1 (de) Verbessertes Plattierungsverfahren
DE602007008063D1 (de) Hydraulikspanner
BRPI0821540A2 (pt) Tecido renal encapsulado
DE602005014851D1 (de) Seilorganisator
BRPI0811092A2 (pt) Método de determinação do grau de um tumor, e, uso de 1 3c-piruvato hiperpolarizado
FR2908513B1 (fr) Systeme d'echantillonnage en temps equivalent
BRPI0912810A2 (pt) "filtro"
EP2091604A4 (en) CATHETER POSITIONING SYSTEM
EP1951337A4 (en) EXTRACORPORAL BLOOD CLEANSING
BRPI0815252A2 (pt) "aparato marcador"
DE502005003619D1 (de) Mehrlumige Aortenkanüle
ITMO20060009U1 (it) Organizer attivita' professionali
UA15971S (uk) Джемпер трикотажний жіночий
ITNU20070003U1 (it) S'ischente

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.